Blood Collection From People With Ovarian Cancer
| Status: | Completed |
|---|---|
| Conditions: | Ovarian Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 10/13/2018 |
| Start Date: | February 13, 2014 |
| End Date: | November 16, 2016 |
Collection of Blood From Patients With Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Background:
- Monocytes are a type of white blood cell found in human blood. They help the immune
system. Researchers have found that monocytes taken from the blood of healthy people can
kill tumor cells. Now they want to know if monocytes taken from the blood of people with
ovarian cancer can kill tumor cells.
- In addition, native host anti-tumor cell mediated immune mechanisms may play a role in
clinical outcome of epithelial ovarian cancer; data indicate that the presence of
intra-tumoral CD3+ T-cells was shown to prognosticate improved outcome in advanced
ovarian cancer. Furthermore, non-cellular components in the blood, such as exosomes, may
influence outcome.
Objective:
- To see if monocytes taken from the blood of people with ovarian cancer can kill tumor
cells.
Eligibility:
- Women 18 years and older with ovarian cancer.
Design:
- Participants will be screened with:
- Medical history and physical exam.
- Blood tests.
- CT scan of the chest, abdomen, and pelvis and/or an MRI. For these scans, they will lie
in a machine that takes pictures of their body.
- A small amount of blood (two tubes) will be collected by needle during one visit.
- Monocytes are a type of white blood cell found in human blood. They help the immune
system. Researchers have found that monocytes taken from the blood of healthy people can
kill tumor cells. Now they want to know if monocytes taken from the blood of people with
ovarian cancer can kill tumor cells.
- In addition, native host anti-tumor cell mediated immune mechanisms may play a role in
clinical outcome of epithelial ovarian cancer; data indicate that the presence of
intra-tumoral CD3+ T-cells was shown to prognosticate improved outcome in advanced
ovarian cancer. Furthermore, non-cellular components in the blood, such as exosomes, may
influence outcome.
Objective:
- To see if monocytes taken from the blood of people with ovarian cancer can kill tumor
cells.
Eligibility:
- Women 18 years and older with ovarian cancer.
Design:
- Participants will be screened with:
- Medical history and physical exam.
- Blood tests.
- CT scan of the chest, abdomen, and pelvis and/or an MRI. For these scans, they will lie
in a machine that takes pictures of their body.
- A small amount of blood (two tubes) will be collected by needle during one visit.
Background:
Using both in vitro and in vivo assays we have shown that human monocytes primed with
Interferons alpha and gamma are tumoricidal and are capable of killing a number of tumor cell
lines and human tumors implanted into immunocompromised mice. We have shown that monocytes
isolated through elutriation at the NIH blood bank and monocytes isolated from anticoagulated
peripheral blood from healthy women from the NIH blood bank are equally capable of killing
tumor cells. No data have been collected as to whether monocytes from patients with Ovarian,
Primary Peritoneal, or Fallopian Tube Cancer have tumoricidal properties. In addition, native
host anti-tumor cell mediated immune mechanisms may play a role in clinical outcome of
epithelial ovarian cancer; data indicate that the presence of intra-tumoral CD3+ T-cells was
shown to prognosticate improved outcome in advanced ovarian cancer. Furthermore, noncellular
components in the blood, such as exosomes, may influence outcome.
Objectives:
To obtain blood samples from patients with ovarian, primary peritoneal or fallopian tube
cancer.
Eligibility:
Females greater than or equal to 18 years of age with a prior diagnosis of ovarian, primary
peritoneal or fallopian tube cancer seen in the Women s Cancer Clinic of the NCI. Patients
must be able and willing to provide informed consent.
Design:
We will collect approximately 20 ml of peripheral blood at a single time point from patients
with ovarian, primary peritoneal or fallopian tube cancer who are not currently on therapy
and are screening for trials, being seen in consultation, or presenting for enrollment on a
clinical trial.
Using both in vitro and in vivo assays we have shown that human monocytes primed with
Interferons alpha and gamma are tumoricidal and are capable of killing a number of tumor cell
lines and human tumors implanted into immunocompromised mice. We have shown that monocytes
isolated through elutriation at the NIH blood bank and monocytes isolated from anticoagulated
peripheral blood from healthy women from the NIH blood bank are equally capable of killing
tumor cells. No data have been collected as to whether monocytes from patients with Ovarian,
Primary Peritoneal, or Fallopian Tube Cancer have tumoricidal properties. In addition, native
host anti-tumor cell mediated immune mechanisms may play a role in clinical outcome of
epithelial ovarian cancer; data indicate that the presence of intra-tumoral CD3+ T-cells was
shown to prognosticate improved outcome in advanced ovarian cancer. Furthermore, noncellular
components in the blood, such as exosomes, may influence outcome.
Objectives:
To obtain blood samples from patients with ovarian, primary peritoneal or fallopian tube
cancer.
Eligibility:
Females greater than or equal to 18 years of age with a prior diagnosis of ovarian, primary
peritoneal or fallopian tube cancer seen in the Women s Cancer Clinic of the NCI. Patients
must be able and willing to provide informed consent.
Design:
We will collect approximately 20 ml of peripheral blood at a single time point from patients
with ovarian, primary peritoneal or fallopian tube cancer who are not currently on therapy
and are screening for trials, being seen in consultation, or presenting for enrollment on a
clinical trial.
- INCLUSION CRITERIA
- Females greater than or equal to 18 years of age with histologically proven ovarian,
primary peritoneal or fallopian tube cancer.
- Currently not on therapy. Must be at least 2 weeks from prior therapy.
- Ability and willingness to provide informed consent to participation.
EXCLUSION CRITERIA
- Children are not eligible.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Phone: 888-624-1937
Click here to add this to my saved trials
